Glioblastoma is the most common and lethal primary malignant brain tumor in adults. Median overall survival from the time of glioblastoma diagnosis is 14 to 15 months among most patients, but only 6 months among elderly patients. Only one-third of patients with glioblastoma survive for 1 year, and less than 5% survive beyond 5 years. The optimal management of glioblastoma requires a multimodal approach. This activity will examine data on appropriate candidates for these treatments and the role of advanced practice clinicians throughout the continuum of care.
eNewsletter with interactive benchmarking
To update advanced practice clinicians on currently available and investigational modalities for treating glioblastoma and to provide strategies for implementing effective clinician-patient communication during the course of the disease.
After completing this activity, participants should be better able to:
- Describe the role of current therapies for the management of patients with glioblastoma
- Evaluate current clinical trial data on novel and emerging agents for the management of patients with glioblastoma
Oncology nurse practitioners, physician assistants, and nurses
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
CNE course advisor: Aileen Staller, DNP, ARNP, AOCNP, Ave Maria University, Ave Maria, Florida
This program has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of May 15, 2018. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Novocure Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or Novocure Inc.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Mehta: consultant: AbbVie, Celgene, Tocagen; stock: Oncoceutics.
The Planning Committee for this activity included Ruth Cohen and Kathleen Wildasin of Continuing Education Alliance; Aileen Staller, DNP, ARNP, AOCNP of Ave Maria University; Katie Zahasky, RN, MA, CNP, of Winona, Minnesota; and Jessica Garner, MMS, PA-C, of the University of the Pacific. The members of the Planning Committee have no significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: May 15, 2018
Expiration date: May 15, 2019
© 2018 Practicing Clinicians Exchange. All Rights Reserved. NCPCE94018